Errors in Figure 4 and Incorrect DNA Sequencing Manufacturer

In the Original Investigation titled “Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response Adaptive-Therapy for HPV⁺ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial,”¹ published online on June 6, 2024, in JAMA Oncology, Figure 4 contained transposed labels on the curves in panel B, and the DNA Safe-Sequencing System was not accurately attributed to Sysmex Inostics Inc. This article was corrected online.